ChiCTR2600126873 版本V1.0 版本创建时间2026/06/17 17:36:38 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600126873 

最近更新日期:

Date of Last Refreshed on:

2026-06-17 17:36:13 

注册时间:

Date of Registration:

2026-06-17 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

TI干预老年认知障碍(记忆障碍)神经调控机制研究

Public title:

Research on the Neuromodulation Mechanism of TI Intervention in Elderly Cognitive Impairment (Memory Impairment)

注册题目简写:

English Acronym:

研究课题的正式科学名称:

TI干预老年认知障碍(记忆障碍)神经调控机制研究

Scientific title:

Research on the Neuromodulation Mechanism of TI Intervention in Elderly Cognitive Impairment (Memory Impairment)

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

徐花 

研究负责人:

徐花 

Applicant:

Hua Xu 

Study leader:

Hua Xu 

申请注册联系人电话:

Applicant telephone:

+86 13851658690

研究负责人电话:

Study leader's telephone:

+86 25 8331 1721

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

miqimama1234@163.com

研究负责人电子邮件:

Study leader's E-mail:

miqimama1234@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省鼓楼区建宁路178号卢龙山庄6栋1单元1204室

研究负责人通讯地址:

江苏省鼓楼区建宁路178号

Applicant address:

Room 1204, Unit 1, Building 6, Lulong Shanzhuang, No. 178 Jianning Road, Gulou District, Jiangsu Province

Study leader's address:

No. 178 Jianning Road, Gulou District, Jiangsu Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

江苏省省级机关医院

Applicant's institution:

Jiangsu Provincial Government Hospital

研究负责人所在单位:

江苏省老年病医院(南京医科大学附属老年医院、江苏省省级机关医院、江苏省老年病医院互联网医院)

Affiliation of the Leader:

Jiangsu Province Geriatric Hospital(Geriatric Hospital of Naning Medical University, Jiangsu Province Official Hospital, Jiangsu Province Geriatric Hospital Telehealth Services)

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2026)院伦意见第025-2号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

江苏省省级机关医院 医学研究伦理审查委员会

Name of the ethic committee:

Jiangsu Province Official Hospital Ethics Committee for Medical Research

伦理委员会批准日期:

Date of approved by ethic committee:

2026-02-28 00:00:00

伦理委员会联系人:

黄健

Contact Name of the ethic committee:

Huang Jian

伦理委员会联系地址:

江苏省鼓楼区建宁路178号

Contact Address of the ethic committee:

No. 178 Jianning Road, Gulou District, Jiangsu Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 25 89699426

伦理委员会联系人邮箱:

Contact email of the ethic committee:

llwyhbgs@126.com

研究实施负责(组长)单位:

江苏省老年病医院(南京医科大学附属老年医院、江苏省省级机关医院、江苏省老年病医院互联网医院)

Primary sponsor:

Jiangsu Province Geriatric Hospital(Geriatric Hospital of Naning Medical University, Jiangsu Province Official Hospital, Jiangsu Province Geriatric Hospital Telehealth Services)

研究实施负责(组长)单位地址:

江苏省鼓楼区建宁路178号

Primary sponsor's address:

No. 178 Jianning Road, Gulou District, Jiangsu Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏省

市(区县):

Country:

China

Province:

Jiangsu

City:

单位(医院):

江苏省老年病医院(南京医科大学附属老年医院、江苏省省级机关医院、江苏省老年病医院互联网医院)

具体地址:

江苏省鼓楼区建宁路178号

Institution
hospital:

Jiangsu Province Geriatric Hospital(Geriatric Hospital of Naning Medical University, Jiangsu Province Official Hospital, Jiangsu Province Geriatric Hospital Telehealth Services)

Address:

No. 178 Jianning Road, Gulou District, Jiangsu Province

经费或物资来源:

江苏省卫生健康委科研项目

Source(s) of funding:

Scientific Research Project of Jiangsu Provincial Health Commission

Target disease:

CognitiveImpairment

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究拟探索一种无创、深部且精准的神经调控技术,即时间干涉脑功能刺激(TI)技术对于记忆障碍的疗效。  

Objectives of Study:

This study aims to explore a non-invasive, deep, and precise neuromodulation technique, namely temporal interference (TI) brain stimulation, for the treatment of memory impairment.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 年龄 60-80 周岁的认知障碍筛查量表异常患者,韦氏记忆量表(WMS)评估存在记忆障碍症状; 2. 头部 MRI 等影像检查未发现影响认知障碍治疗的异常; 3. 病情稳定、并发症控制良好,无认知障碍治疗禁忌症及干扰临床评价的情况。

Inclusion criteria

1. Patients aged 60-80 who have abnormal results on cognitive impairment screening tests show memory problems on the Wechsler Memory Scale (WMS); 2. Head MRI and other imaging tests didn't find any issues that would affect cognitive impairment treatment; 3. Condition is stable, complications are well controlled, and there are no contraindications for cognitive impairment treatment or issues that would interfere with clinical evaluation.

排除标准:

1.既往重大神经系统疾病(癫痫、痴呆、帕金森病);
2.严重心脏或呼吸系统疾病;
3.严重的肝肾功能不全;
4.颅内金属植入物;
5.存在活动性出血或凝血功能障碍;

Exclusion criteria:

1. Past major neurological diseases (epilepsy, dementia, Parkinson's disease); 2. Serious heart or respiratory diseases; 3. Severe liver or kidney dysfunction; 4. Intracranial metal implants; 5. Active bleeding or blood clotting disorders.

研究实施时间:

Study execute time:

From 2026-01-01 00:00:00 To 2028-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-01 00:00:00 To 2027-05-31 00:00:00  

干预措施:

Interventions:

组别:

时间干涉经颅电刺激治疗

样本量:

15

Group:

Time-interference Transcranial Electrical Stimulation Therapy

Sample size:

干预措施:

时间干涉经颅电刺激治疗

干预措施代码:

Intervention:

temporal inference stimulation

Intervention code:

组别:

时间干涉经颅电刺激假刺激

样本量:

15

Group:

sham inference stimulation

Sample size:

干预措施:

时间干涉经颅电刺激假刺激

干预措施代码:

Intervention:

sham inference stimulation

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏省 

市(区县):

 

Country:

China 

Province:

Jiangsu 

City:

 

单位(医院):

江苏省老年病医院(南京医科大学附属老年医院、江苏省省级机关医院、江苏省老年病医院互联网医院) 

单位级别:

三级甲等 

Institution
hospital:

Jiangsu Province Geriatric Hospital(Geriatric Hospital of Naning Medical University, Jiangsu Province Official Hospital, Jiangsu Province Geriatric Hospital Telehealth Services)

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

DTI各向异性(FA值)

指标类型:

次要指标

Outcome:

DTI fractional anisotropy (FA) values

Type:

Secondary indicator

测量时间点:

30天干预结束后

测量方法:

功能核磁扫描DTI序列

Measure time point of outcome:

30 days after intervention

Measure method:

functional MRI DTI sequence

指标中文名:

静息态fMRI(ReHo功能连接)

指标类型:

次要指标

Outcome:

resting state fMRI (ReHo functional connectivity)

Type:

Secondary indicator

测量时间点:

30天治疗结束后

测量方法:

功能核磁扫描

Measure time point of outcome:

30 days after intervention

Measure method:

functional MRI scan

指标中文名:

θ-γ PAC强度

指标类型:

次要指标

Outcome:

θ-γ PAC strength

Type:

Secondary indicator

测量时间点:

30天治疗后

测量方法:

Measure time point of outcome:

30 days after intervention

Measure method:

指标中文名:

RAVLT延迟回忆

指标类型:

主要指标

Outcome:

RAVLT delayed recall

Type:

Primary indicator

测量时间点:

30天治疗后

测量方法:

RAVLT延迟回忆量表评估

Measure time point of outcome:

30 days after intervention

Measure method:

Assessment of RAVLT delayed recall

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 60 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究者采用随机数字表法产生随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

The researchers used a random number table to generate the random sequence

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

单盲,对评估者隐藏分组

Blinding:

Single blind study with blinded-evaluators

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

论文发表后半年内,国家人口健康科学数据中心,https://www.ncmi.cn/index.html

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Within six months after the paper is published,National Population Health Science Data Center, https://www.ncmi.cn/index.html

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究采用统一设计的CRF表进行临床数据采集,所有CRF由经过统一培训并授权的研究人员填写。研究人员应确保数据真实、准确、完整、及时填写,不得随意修改原始记录。如需修改,应保留原始记录,并注明修改日期、修改原因及修改人签名。所有原始资料均应妥善保存,以备伦理检查、监查及稽查。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

In this study, a uniformly designed CRF (Case Report Form) was used for clinical data collection. All CRFs were completed by researchers who received standardized training and were authorized. The researchers must ensure that the data are authentic, accurate, complete, and filled out in a timely manner, and must not arbitrarily modify the original records. If modifications are necessary, the original record shall be retained, and the date of modification, reason for modification, and signature of the modifier shall be indicated. All original documents should be properly preserved for ethics review, monitoring, and auditing.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-06-17 17:36:13